AAA
KROS icon

Affinity Asset Advisors’s Keros Therapeutics KROS Stock Holding History

Affinity Asset Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,500
Closed -$495K – 65
2021
Q3 		$495K Buy
+12,500
New +$445K 0.13% 68

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Affinity Asset Advisors's KROS Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Keros Therapeutics (KROS) in Q4 2021, closing a stake of 12,500 shares — an estimated $495K sold.

Affinity Asset Advisors first reported a position in KROS in Q3 2021 and held it in 1 quarter. The position peaked at $495K in Q3 2021. 99 funds tracked by Wall St. Rank hold KROS as of Q4 2021.

  • Affinity Asset Advisors reported no remaining Keros Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 12,500 Keros Therapeutics shares in Q4 2021, an estimated $495K.
  • Affinity Asset Advisors first reported a position in Keros Therapeutics in Q3 2021 and held it in 1 quarter.
  • Affinity Asset Advisors's Keros Therapeutics position peaked at $495K in Q3 2021.
  • 99 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.